Current Anesthesiology Reports

, Volume 8, Issue 4, pp 337–341 | Cite as

A Summary of Newer and Safer Opioid Formulations

  • Michelle DangEmail author
Pain Medicine (GJ Meredith, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pain Medicine


Purpose of the Review

The review provides a brief summary of newer and safer opioid formulations that are currently on the market.

Recent Findings

The FDA currently has on the market seven opioid formulations that have abuse-deterrent properties.


While prescription opioid abuse continues to be a problem today, the development of abuse-deterrent opioids may mitigate the incidence of abuse.


Opioids Abuse Abuse deterrent Oxycodone Morphine Opioid epidemic Hydrocodone Oxycontin Hysingla Fda Cdc Roxybond Morphabond Embeda Xtampza Arymo Opioid abuse Opioid misuse Misuse Overdose 


Compliance with Ethical Standards

Conflict of Interest

Michelle Dang declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–45. Updated guidelines on CDC recommendations. CrossRefPubMedGoogle Scholar
  2. 2.
    •• U.S. Food and Drug Administration (2018, June 14). Opioid medications and FDA’s 2018 strategic policy roadmap. Retrieved from Overview of agency updates on opioid crisis.
  3. 3.
    World Health Organization. Lexicon of alcohol and drug terms published by the World Health Organization. Retrieved from
  4. 4.
    Litman RS, Pagán OH, Cicero TJ. Abuse-deterrent opioid formulations. Anesthesiology. 2018;128:1015–26.CrossRefGoogle Scholar
  5. 5.
    Moorman-Li R, Motycka CA, Inge LD, Congdon JM, Hobson S, Pokropski B. A review of abuse-deterrent opioids for chronic nonmalignant pain. Pharm Ther. 2012;37(7):412–8.Google Scholar
  6. 6.
    Vadivelu N, Schermer E, Kodumudi G, Berger JM. The clinical applications of extended-release abuse deterrent opioids. CNS Drugs. 2016;30:637–46. Scholar
  7. 7.
    •• U.S. Food and Drug Administration (2018, April 23). Abuse deterrent opioid analgesics. Retrieved from Overview of available ADF today.
  8. 8.
    Seth P, Rudd R, Noonan R, Haegerich T. Quantifying the epidemic of prescription opioid overdose deaths. Am J Public Health. 2018;108(4):500–2.CrossRefGoogle Scholar
  9. 9.
    U.S. Food and Drug Administration (2018, April 26). FDA opioids action plan. Retrieved from
  10. 10.
    Ballantyne J. Opioids for the treatment of chronic pain: mistakes made, lessons learned, and future directions. Anesth Analg. 2017;125(5):1769–78.CrossRefGoogle Scholar
  11. 11.
    Bonnie R, Ford M, Phillips J. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. National Academies of Sciences, Engineering, and Medicine. 2017; Washington, DC: The National Academies Press.
  12. 12.
    Covvey JR. Recent developments toward the safer use of opioids, with a focus on hydrocodone. Res Soc Adm Pharm. 2015;11:901–8.CrossRefGoogle Scholar
  13. 13.
    Dhillon S. Hydrocodone bitartrate ER (Hysingla® ER): a review in chronic pain. Clin Drug Investig. 2016;36:969–80. Scholar
  14. 14.
    Taber L. Safety and effectiveness of once-daily Hysingla extended-release tablets in patients with baseline depression or anxiety. Pain Manag. 2017;7(6):473–88. Scholar
  15. 15.
    Woodcock J, Throckmorton D. The FDA’s approach to the prescription opioid problem. Clinical pharmacology and therapeutics. 2018, 103, 954, 955.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Texas Orthopaedic and Sports MedicineTomballUSA

Personalised recommendations